source
- Blackstone pledges up to $1.5 billion to fund Pfizer's obesity drug berobenatide developmentBlackstone Life Sciences has agreed to provide up to $1.5 billion to support the research and development of Pfizer's obesity candidate, berobenatide, which originated from the former Metsera progr…
- Biopharma layoffs rise YoY in October but overall trend points down for 2026October marked the first time this year that both the number of biotech and pharma firms announcing workforce cuts and the total employees affected rose compared with 2025. Three additional employ…